Literature DB >> 16281965

Erythropoietin-induced, antibody-mediated pure red cell aplasia.

Jérôme Rossert1.   

Abstract

Pure red cell aplasia (PRCA) is a rare haematological condition that is characterized by severe aregenerative anaemia due to an almost complete cessation of red blood cell production. While antibody-mediated PRCA was extremely rare before 1998, the incidence of this disorder increased sharply after 1998 in patients receiving subcutaneous epoetin alfa produced by Ortho-Biotech and marketed outside the USA. The diagnosis of antibody-mediated PRCA relies mostly on the results of bone marrow biopsy or aspirate, which shows an absence of erythroid precursors and/or red cell maturation arrest while counts of white cell and platelet precursors are normal, and on the identification of circulating anti-erythropoietin antibodies. Retrospective analysis of PRCA cases has shown that immunosuppressive therapy can induce a disappearance of anti-erythropoietin antibodies in most patients. Eur J Clin Invest 2005; 35 (Suppl. 3): 95-99.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16281965     DOI: 10.1111/j.1365-2362.2005.01536.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  10 in total

1.  Feasibility of a multiplex flow cytometric bead immunoassay for detection of anti-epoetin alfa antibodies.

Authors:  John Ferbas; John Thomas; John Hodgson; Amitabh Gaur; Nicole Casadevall; Steven J Swanson
Journal:  Clin Vaccine Immunol       Date:  2007-07-18

2.  Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.

Authors:  Yulia Vugmeyster; Xin Xu; Frank-Peter Theil; Leslie A Khawli; Michael W Leach
Journal:  World J Biol Chem       Date:  2012-04-26

3.  Antiepoetin antibody-related pure red cell aplasia: successful remission with cessation of recombinant erythropoietin alone.

Authors:  Daisuke Katagiri; Maki Shibata; Takashi Katsuki; Shoichi Masumoto; Ai Katsuma; Eri Minami; Taro Hoshino; Tsuyoshi Inoue; Manami Tada; Fumihiko Hinoshita
Journal:  Clin Exp Nephrol       Date:  2010-07-23       Impact factor: 2.801

Review 4.  Biosimilars: recent developments.

Authors:  A Covic; M K Kuhlmann
Journal:  Int Urol Nephrol       Date:  2007-02-27       Impact factor: 2.370

Review 5.  Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies.

Authors:  David H Henry
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 6.  Polymer-based sustained-release dosage forms for protein drugs, challenges, and recent advances.

Authors:  Fei Wu; Tuo Jin
Journal:  AAPS PharmSciTech       Date:  2008-12-16       Impact factor: 3.246

7.  Efficacy and safety of subcutaneous administration of lyophilized powder of alfa-erythropoietin to maintain hemoglobin concentrations among hemodialysis patients.

Authors:  Bancha Satirapoj; Rattanawan Dispan; Ouppatham Supasyndh
Journal:  Int J Nephrol Renovasc Dis       Date:  2017-09-20

8.  The Use of Darbepoetin to Stimulate Erythropoiesis in the Treatment of Anemia of Chronic Kidney Disease in Dogs.

Authors:  E H Fiocchi; L D Cowgill; D C Brown; J E Markovich; S Tucker; M A Labato; M B Callan
Journal:  J Vet Intern Med       Date:  2017-03-03       Impact factor: 3.333

9.  Rituximab: A viable treatment option for epoetin-induced pure red cell aplasia.

Authors:  S A Mahajan; N Nandagopal; M Soni; R A Annigeri
Journal:  Indian J Nephrol       Date:  2015 Nov-Dec

10.  Pure Red Cell Aplasia Following Interleukin-2 Therapy.

Authors:  Janice P Dutcher; Wen Fan; Peter H Wiernik
Journal:  J Investig Med High Impact Case Rep       Date:  2016-04-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.